Overview
Publication
J Infect Dis. 2011 Mar; 203(5):610-9.
PubMed ID: 21282192
Title
Phase 1 safety and immunogenicity testing of DNA and recombinant Modified Vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Authors
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, Derosa SC, Defawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; the National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network
Abstract
Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine. This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.